Universal 4SCAR7U T Cell Therapy (Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2024/11/20 20:00:31

Base Information

Drug NameUniversal 4SCAR7U T Cell Therapy (Shenzhen Geno-Immune Medical Institute)
Drug Alias NameUniversal CD7-specific CAR gene-engineered T cellsTherapy (Shenzhen Geno-Immune Medical Institute)4SCAR7U T cells
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-T
Mechanisms of ActionT-cell antigen CD7 modulators
TargetsT-cell antigen CD7
Therapy Area/IndicationsLymphomaLeukemia, Myeloid, AcutePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShenzhen Geno-Immune Medical Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShenzhen Geno-Immune Medical Institute
Active IndicationsN/A
Inactive IndicationsLymphomaLeukemia, Myeloid, AcutePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A